Insider Buying: Bath & Body Works (NYSE:BBWI) Director Buys $99,562.00 in Stock

Bath & Body Works, Inc. (NYSE:BBWI) Director Stephen Steinour bought 6,700 shares of the business’s stock in a transaction dated Friday, November 21st. The stock was acquired at an average cost of $14.86 per share, for a total transaction of $99,562.00. Following the purchase, the director owned 48,175 shares in the company, valued at approximately $715,880.50. This trade represents a 16.15% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Bath & Body Works Price Performance

Shares of BBWI opened at $17.40 on Thursday. The stock has a market cap of $3.59 billion, a PE ratio of 5.16, a P/E/G ratio of 0.86 and a beta of 1.53. Bath & Body Works, Inc. has a 12 month low of $14.27 and a 12 month high of $41.87. The stock’s 50-day moving average is $24.02 and its two-hundred day moving average is $27.83.

Bath & Body Works (NYSE:BBWI) last released its quarterly earnings results on Thursday, November 20th. The company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.05). Bath & Body Works had a negative return on equity of 48.43% and a net margin of 9.88%.The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same quarter in the prior year, the company earned $0.49 EPS. The firm’s revenue was down 1.0% compared to the same quarter last year. Bath & Body Works has set its FY 2025 guidance at 2.870- EPS. Q4 2025 guidance at 1.700- EPS. On average, research analysts anticipate that Bath & Body Works, Inc. will post 3.3 earnings per share for the current year.

Bath & Body Works Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Friday, November 21st will be paid a $0.20 dividend. The ex-dividend date is Friday, November 21st. This represents a $0.80 annualized dividend and a dividend yield of 4.6%. Bath & Body Works’s payout ratio is 24.62%.

Institutional Investors Weigh In On Bath & Body Works

Several hedge funds have recently made changes to their positions in BBWI. First Horizon Corp purchased a new stake in Bath & Body Works in the 3rd quarter worth about $29,000. Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in Bath & Body Works in the second quarter valued at approximately $33,000. SVB Wealth LLC bought a new stake in Bath & Body Works in the first quarter worth $35,000. Geneos Wealth Management Inc. boosted its stake in shares of Bath & Body Works by 217.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock worth $35,000 after acquiring an additional 801 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in Bath & Body Works by 63.3% during the second quarter. Parallel Advisors LLC now owns 1,241 shares of the company’s stock worth $37,000 after purchasing an additional 481 shares during the period. Hedge funds and other institutional investors own 95.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on BBWI shares. Raymond James Financial reaffirmed a “market perform” rating on shares of Bath & Body Works in a research report on Wednesday, November 12th. Telsey Advisory Group downgraded Bath & Body Works from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $38.00 to $17.00 in a research note on Friday, November 21st. Barclays reduced their price target on shares of Bath & Body Works from $28.00 to $18.00 and set an “equal weight” rating for the company in a report on Friday, November 21st. Weiss Ratings reissued a “hold (c-)” rating on shares of Bath & Body Works in a report on Wednesday, October 8th. Finally, Citigroup lowered their target price on shares of Bath & Body Works from $35.00 to $21.00 and set a “buy” rating on the stock in a research note on Friday, November 21st. Six equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bath & Body Works presently has an average rating of “Hold” and a consensus price target of $25.17.

About Bath & Body Works

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.